Addressing Unmet Needs in Corneal and Anterior Segment Diseases
A differentiated therapeutic approach targeting high-value, underserved rare ocular diseases
- Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in neuropathic pain.
- The chemerin receptor is a G protein-coupled receptor (GPCR) found on select immune, epithelial, and dorsal root ganglion/spinal cord neuronal cells.
- Activation of chemerin receptor has been shown to modulate the resolution of inflammation and neuropathic pain.
- Urcosimod can potentially benefit patients suffering from ocular pain and ocular inflammation.
- A chronic pain condition due to nerve damage or dysfunction in the corneal region.
- Severe eye pain, burning, foreign body sensation and light sensitivity (photophobia)
- Can result from trauma, surgery (e.g., refractive surgery), infections, or conditions like dry eye disease that affect corneal nerves.
- The pain is due to abnormal signalling in the corneal nerves, which may become sensitized or dysfunctional, leading to persistent pain.
- No FDA approved treatment.
- OKYO is the first company to receive an investigational new drug (IND) application clearance by FDA to clinically evaluate a drug specifically to treat NCP
